Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual versus oral aspirin dose comparison for platelet aggregation inhibition in adults at increased cardiovascular risk
2013-002980-24Phase 2Active
- Sponsor
- IRCCS San Raffaele Pisana
- Start
- Aug 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aspirin in cardiac morbidity (3 arms), sponsored by IRCCS San Raffaele Pisana. Primary endpoint: Change in platelet aggregation effect after 12 weeks of treatment. Started Aug 2013; status: active.
02
Drugs
aspirin
03
Conditions
cardiac morbidity
Beyond the preview
Go deeper on 2013-002980-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002980-24.